Lilly(Eli) (LLY) Market Cap (1999 - 2026)
Lilly(Eli) (LLY) market cap from Nov 1, 1999 to Jul 20, 2026. The current Lilly(Eli) (LLY) market cap is $1.03T. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Market Cap
Lilly(Eli) (LLY) Market Cap CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +15.66% |
| 3 Years TTM | +37.73% |
| 5 Years TTM | +39.36% |
| 10 Years TTM | +26.00% |
| All Time TTM | +10.31% |
Annual Market Cap change of Lilly(Eli) (LLY)
| Year | Market Cap | Change |
|---|---|---|
| 2026 | $1.03T | +6.39% |
| 2025 | $964B | +38.57% |
| 2024 | $696B | +32.61% |
| 2023 | $525B | +59.18% |
| 2022 | $330B | +31.57% |
| 2021 | $250B | +63.51% |
| 2020 | $153B | +27.52% |
| 2019 | $120B | +1.72% |
| 2018 | $118B | +32.72% |
| 2017 | $89B | +14.37% |
| 2016 | $78B | -13.01% |
| 2015 | $89B | +21.20% |
| 2014 | $74B | +33.95% |
| 2013 | $55B | +24.87% |
| 2012 | $44B | +18.67% |
| 2011 | $37B | +18.61% |
| 2010 | $31B | -1.88% |
| 2009 | $32B | -11.32% |
| 2008 | $36B | -24.57% |
| 2007 | $48B | +2.48% |
| 2006 | $47B | -7.93% |
| 2005 | $51B | -0.28% |
| 2004 | $51B | -19.31% |
| 2003 | $63B | +10.76% |
| 2002 | $57B | -19.15% |
| 2001 | $70B | -15.60% |
| 2000 | $83B | +39.94% |
| 1999 | $59B | N/A |
Comparison Lilly(Eli) (LLY) market cap with competitors
Lilly(Eli) (LLY) market cap is $1.03T.
| Ticker | Name | Market Cap | Upside |
|---|---|---|---|
| JNJ | Johnson & Johnson | $594.97B | -41.98% |
| ABBV | Abbvie Inc | $432.22B | -57.85% |
| AZN | Astrazeneca plc | $295.54B | -71.18% |
| MRK | Merck & Co Inc | $291.57B | -71.57% |
| NVS | Novartis AG | $288.93B | -71.82% |
| NVO | Novo Nordisk | $224.93B | -78.07% |
| AMGN | AMGEN Inc | $193.39B | -81.14% |
| GILD | Gilead Sciences Inc | $163.57B | -84.05% |
| PFE | Pfizer Inc | $141.25B | -86.23% |
| BMY | Bristol-Myers Squibb Company | $119.63B | -88.33% |
| SNY | Sanofi | $105.20B | -89.74% |
| GSK | GSK Plc | $104.78B | -89.78% |
| BIIB | Biogen Inc | $29.03B | -97.17% |
| GRFS | Grifols SA | $4.91B | -99.52% |
| OGN | Organon & Company | $3.54B | -99.65% |
| AMRN | Amarin Corp | $303.37M | -99.97% |
| SCLX | Scilex Holding Company | $78.29M | -99.99% |
| MIRA | Mira Pharmaceuticals Inc | $39.50M | -100.00% |
| NSRX | Nasus Pharma Ltd | $28.10M | -100.00% |
| MDCXW | Medicus Pharma Ltd warrant | $19.20M | -100.00% |
| MDCX | MDCorp | $13.93M | -100.00% |